Zhdan V. N., Kyrian O. A., Babanina M. Yu., Ivanytskyi I. V., Tkachenko M. V., Lebid V. G.

AUTOIMMUNE HEPATITIS AND THE COMPLEXITY OF ITS MANAGEMENT: A CLINICAL CASE

---

Show/Download

About the author:

Zhdan V. N., Kyrian O. A., Babanina M. Yu., Ivanytskyi I. V., Tkachenko M. V., Lebid V. G.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Autoimmune hepatitis is considered a rare autoimmune inflammatory disease of the liver, which has a high mortality in the absence of therapy. A feature of autoimmune hepatitis is a wide range of clinical symptoms, from asymptomatic (in 25-37% of patients) for several years to an acute course of the disease, which complicates the timely diagnosis of such patients. In addition, the course of autoimmune hepatitis in 14-44% of cases is complicated by other concomitant autoimmune diseases, such as autoimmune thyroiditis or type I diabetes. The complexity of managing patients with autoimmune hepatitis is often due to overlap syndromes with primary biliary cholangitis or primary sclerosing cholangitis. Histological examination and diagnostic markers of autoimmune hepatitis, which has an overlap syndrome with primary biliary cholangitis, play the most important role in the verification of the diagnosis, especially in case of simultaneous manifestation of diseases. This paper presents a clinical case of a patient with a crossover course of autoimmune hepatitis and primary biliary cholangitis, which had an asymptomatic onset and required a liver biopsy to confirm the overlap syndrome. We aimed to investigate the possibilities of management and prevention of complications in a patient with autoimmune hepatitis who had an overlap syndrome with primary biliary cholangitis. Using the example of this clinical case, the tactics of preventing the progression of the disease and the possibility of preventing the appearance of side effects of therapy in a patient with the overlap syndrome of autoimmune hepatitis and primary biliary cholangitis are highlighted. The presented research data may interest family doctors, therapists, gastroenterologists and doctors of other specialties.

Tags:

Bibliography:

1. Zhdan VN, Tkachenko MV, Babanina MYu, Kitura YeM, Kyrian OA. The most common causes of comorbidity in patients with rheumatoid arthritis. Family Medicine. 2021;4(96):79-83. [in Ukrainian].
2. Zhdan VN, Dorofeуev AE, Kyrian OA, Babanina MYu, Volchenko HV, Tkachenko MV. Overlap syndrome of autoimmune liver disease in a patient with ulcerative colitis. Actual Problems of the Modern Medicine. 2016;16(2(54):89-92.
3. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of autoimmune hepatitis 2022. Clin Mol Hepatol. 2023;29(3):542-92. DOI: 10.3350/cmh.2023.0087.
4. Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int. 2021;15(2):223-57. DOI: 10.1007/s12072-021-10170-1.
5. Kim BH, Choi HY, Ki M, Kim KA, Jang ES, Jeong SH. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 2017;3(12(8)):e0182391. DOI: 10.1371/journal.pone. 0182391.
6. Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671- 722. DOI: 10.1002/hep.31065.
7. Muratori P, Fabbri A, Lalanne C, Lenzi M, Muratori L. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol. 2015;27:1175-79. DOI: 10.1097/MEG.0000000000 000424.
8. Tanaka A, Ma X, Yokosuka O, Weltman M, You H, Amarapurkar DN, et al. Autoimmune liver diseases in the Asia-Pacific region. Proceedings of APASL symposium on AIH and PBC 2016; Hepatol Int. 2016;10(6):909-15. DOI: 10.1007/s12072-016-9767-9.
9. Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013;58(2):326-43.
10. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433-37. DOI: 10.1007/s10620-006-9665-4.
11. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1):15-20.
12. Wong GW, Yeong T, Lawrence D, Yeoman AD, Verma S, Heneghan MA. Concurrent extrahepatic autoimmunity in autoimmune hepatitis: implications for diagnosis, clinical course and long-term outcomes. Liver Int. 2017;37:449-57. DOI: 10.1111/liv.13236.
13. Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther. 2012;36:517-33. DOI: 10.1111/j.1365-2036.2012.05223.x.
14. O’Brien C, Joshi S, Feld JJ, Guindi M, Dienes HP, Heathcote EJ. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology. 2008;48:550-56. DOI: 10.1002/hep.22380.
15. Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44:85-90. DOI: 10.1002/hep.21229.
16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172-93. DOI: 10.1016/j.jhep.2018.06.024.
17. Buckley L, Humphrey MB. Glucocorticoid-Induced Osteoporosis. N Engl J Med. 2018;379:2547-56. DOI: 10.1056/NEJMcp1800214.
18. Park SY, Gong HS, Kim KM, Kim D, Kim HY, Jeon CH, et al. Korean guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Metab. 2018;25:195-211. DOI: 10.11005/jbm.2018.25. 4.195.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 4, 171, 179-187 pages, index UDC 616.36-002:616.017

DOI:

10.29254/2077-4214-2023-4-171-179-187